|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-bearing funds with Federal Reserve Bank | ||||||||||||||||||||
| Interest earning deposits with banks | ||||||||||||||||||||
| Interest-earning deposits with banks and other cash and cash equivalents | ||||||||||||||||||||
| Federal funds sold and securities purchased under resale agreements | ||||||||||||||||||||
| Total cash, cash equivalents, and restricted cash | ||||||||||||||||||||
| Investment securities available for sale, at fair value | ||||||||||||||||||||
| Investment securities held to maturity | ||||||||||||||||||||
| Investment securities available for sale | ||||||||||||||||||||
| Loans held for sale (includes $41,083 and $33,448 measured at fair value, respectively) | ||||||||||||||||||||
| Loans, net of deferred fees and costs | ||||||||||||||||||||
| Allowance for loan losses | ||||||||||||||||||||
| Loans, net | ||||||||||||||||||||
| Cash surrender value of bank-owned life insurance | ||||||||||||||||||||
| Premises, equipment, and software, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Non-interest-bearing deposits | ||||||||||||||||||||
| Interest-bearing deposits | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Federal funds purchased and securities sold under repurchase agreements | ||||||||||||||||||||
| Other short-term borrowings | ||||||||||||||||||||
| Federal funds purchased, securities sold under repurchase agreements, and other short-term borrowings | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity | ||||||||||||||||||||
| Shareholders' equity: | ||||||||||||||||||||
| Preferred stock - no par value; authorized 100,000,000 shares; issued 22,000,000 | ||||||||||||||||||||
| Common stock - $1.00 par value; authorized 342,857,142 shares; issued 172,734,160 and 172,185,507, respectively; outstanding 138,813,060 and 141,165,908, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Treasury stock, at cost; 33,921,100 and $31,019,599 shares, respectively | ||||||||||||||||||||
| Accumulated other comprehensive income (loss), net | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total Synovus Financial Corp. shareholders' equity | ||||||||||||||||||||
| Noncontrolling interest in subsidiary | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
| Treasury stock, shares at cost (in shares) | ||||||||||||||||||||
Loading...
